CITIUS PHARMAC (Germany) Probability of Future Stock Price Finishing Under 2.59
| 47N Stock | EUR 3.29 0.00 0.00% |
CITIUS |
CITIUS PHARMAC Target Price Odds to finish below 2.59
The tendency of CITIUS Stock price to converge on an average value over time is a known aspect in finance that investors have used since the beginning of the stock market for forecasting. However, many studies suggest that some traded equity instruments are consistently mispriced before traders' demand and supply correct the spread. One possible conclusion to this anomaly is that these stocks have additional risk, for which investors demand compensation in the form of extra returns.
| Current Price | Horizon | Target Price | Odds to drop to € 2.59 or more in 90 days |
| 3.29 | 90 days | 2.59 | nearly 4.59 |
Based on a normal probability distribution, the odds of CITIUS PHARMAC to drop to € 2.59 or more in 90 days from now is nearly 4.59 (This CITIUS PHARMAC DL probability density function shows the probability of CITIUS Stock to fall within a particular range of prices over 90 days) . Probability of CITIUS PHARMAC DL price to stay between € 2.59 and its current price of €3.29 at the end of the 90-day period is roughly 2.79 .
Assuming the 90 days horizon CITIUS PHARMAC has a beta of 0.0681. This suggests as returns on the market go up, CITIUS PHARMAC average returns are expected to increase less than the benchmark. However, during the bear market, the loss on holding CITIUS PHARMAC DL will be expected to be much smaller as well. Additionally CITIUS PHARMAC DL has a negative alpha, implying that the risk taken by holding this instrument is not justified. The company is significantly underperforming the Dow Jones Industrial. CITIUS PHARMAC Price Density |
| Price |
Predictive Modules for CITIUS PHARMAC
There are currently many different techniques concerning forecasting the market as a whole, as well as predicting future values of individual securities such as CITIUS PHARMAC DL. Regardless of method or technology, however, to accurately forecast the stock market is more a matter of luck rather than a particular technique. Nevertheless, trying to predict the stock market accurately is still an essential part of the overall investment decision process. Using different forecasting techniques and comparing the results might improve your chances of accuracy even though unexpected events may often change the market sentiment and impact your forecasting results.CITIUS PHARMAC Risk Indicators
For the most part, the last 10-20 years have been a very volatile time for the stock market. CITIUS PHARMAC is not an exception. The market had few large corrections towards the CITIUS PHARMAC's value, including both sudden drops in prices as well as massive rallies. These swings have made and broken many portfolios. An investor can limit the violent swings in their portfolio by implementing a hedging strategy designed to limit downside losses. If you hold CITIUS PHARMAC DL, one way to have your portfolio be protected is to always look up for changing volatility and market elasticity of CITIUS PHARMAC within the framework of very fundamental risk indicators.α | Alpha over Dow Jones | -1.57 | |
β | Beta against Dow Jones | 0.07 | |
σ | Overall volatility | 2.95 | |
Ir | Information ratio | -0.21 |
CITIUS PHARMAC Alerts and Suggestions
In today's market, stock alerts give investors the competitive edge they need to time the market and increase returns. Checking the ongoing alerts of CITIUS PHARMAC for significant developments is a great way to find new opportunities for your next move. Suggestions and notifications for CITIUS PHARMAC DL can help investors quickly react to important events or material changes in technical or fundamental conditions and significant headlines that can affect investment decisions.| CITIUS PHARMAC DL generated a negative expected return over the last 90 days | |
| CITIUS PHARMAC DL has high historical volatility and very poor performance | |
| CITIUS PHARMAC DL has high likelihood to experience some financial distress in the next 2 years | |
| Net Loss for the year was (23.66 M) with profit before overhead, payroll, taxes, and interest of 0. | |
| CITIUS PHARMAC DL has accumulated about 115.66 M in cash with (22.02 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.79. |
CITIUS PHARMAC Technical Analysis
CITIUS PHARMAC's future price can be derived by breaking down and analyzing its technical indicators over time. CITIUS Stock technical analysis helps investors analyze different prices and returns patterns as well as diagnose historical swings to determine the real value of CITIUS PHARMAC DL. In general, you should focus on analyzing CITIUS Stock price patterns and their correlations with different microeconomic environments and drivers.
CITIUS PHARMAC Predictive Forecast Models
CITIUS PHARMAC's time-series forecasting models is one of many CITIUS PHARMAC's stock analysis techniques aimed to predict future share value based on previously observed values. Time-series forecasting models are widely used for non-stationary data. Non-stationary data are called the data whose statistical properties, e.g., the mean and standard deviation, are not constant over time, but instead, these metrics vary over time. This non-stationary CITIUS PHARMAC's historical data is usually called time series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the stock market movement and maximize returns from investment trading.
Things to note about CITIUS PHARMAC DL
Checking the ongoing alerts about CITIUS PHARMAC for important developments is a great way to find new opportunities for your next move. Our stock alerts and notifications screener for CITIUS PHARMAC DL help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.
| CITIUS PHARMAC DL generated a negative expected return over the last 90 days | |
| CITIUS PHARMAC DL has high historical volatility and very poor performance | |
| CITIUS PHARMAC DL has high likelihood to experience some financial distress in the next 2 years | |
| Net Loss for the year was (23.66 M) with profit before overhead, payroll, taxes, and interest of 0. | |
| CITIUS PHARMAC DL has accumulated about 115.66 M in cash with (22.02 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.79. |
Other Information on Investing in CITIUS Stock
CITIUS PHARMAC financial ratios help investors to determine whether CITIUS Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in CITIUS with respect to the benefits of owning CITIUS PHARMAC security.